Brenda De Keersmaecker on the Difference in the Results of this Study in Patients Treated with Ipilimumab Alone

Brenda De Keersmaecker on the Difference in the Results of this Study in Patients Treated with Ipilimumab Alone

User Photo
Cancer-News

5 months
3 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:

Brenda De Keersmaecker of eTheRNA Immunotherapies discusses a strong link between T cell activation and durable clinical benefit (DCB) in late stage melanoma patients following vaccination with TriMix and tumor associated antigen mRNA modified dendritic cells plus ipilimumab.

__________

For four cycles, monocyte-derived dendritic cells electroporated with mRNA encoding CD70, CD40 ligand, and constitutively active TLR4 (TriMix), as well as TAAs tyrosinase, gp100, MAGE-A3, and MAGE-C2 were administered along with ipilimumab. A supplementary vaccine was provided for 18/39 patients prior to the first administration of ipilimumab. In previously collected peripheral mononuclear blood cells, which were available for 15 of the patients, TAA-specific T-cell responses were analyzed. Following in vitro T-cell stimulation in 12 patients, vaccine-induced immune responses were observed for this subgroup of patients. Immune responses observed in patients with complete or partial response were substantially stronger and wider, and displayed a higher degree of multifunctionality relative to responses in patients with stable or worsening disease.

Lead author, Dr Brenda De Keersmaecker, commented: “TriMixDC-MEL IPI treatment results in strong vaccine- specific T-cell responses, mainly in patients obtaining durable clinical responses. These results show the power of TriMix-based TAA-specific vaccination in combination with immune checkpoint blockade to break cancer immune tolerance and to give long-term clinical response.”

Up Next Autoplay